Overview

Extended Follow-Up After Islet Transplantation in T1D

Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to provide patients who have received at least one islet transplant as a previous participant in a Clinical Islet Transplantation Consortium (CIT) clinical trial with maintenance immunosuppressive medications and to collect information about the safety of the medications and islet function.
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators:
Clinical Islet Transplantation Consortium
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Treatments:
Cyclosporine
Cyclosporins
Immunosuppressive Agents
Mycophenolate mofetil
Mycophenolic Acid
Sirolimus
Tacrolimus